Pembrolizumab Induced Grover-like Eruption in a Colorectal Liver Metastasis Patient: A Case and Review
Journal of Dermatology Research · 02.06.2026 · 7 (2) · 1-7
DOI: 10.46889/jdr.2026.7205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Dermatology Research, online erschienen am 02.06.2026. Verfasst von Tara Ghalambor und 1 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
Immune Checkpoint Inhibitors (ICIs) are effective in treating advanced malignancies but are associated with immune-related Adverse Events (irAEs), most commonly involving the skin. Transient Acantholytic Dermatosis (TAD, Grover disease) is a rare cutaneous irAE, comprising only 0.2% of reported cases. Case Presentation: A 64-year-old woman with metastatic colorectal carcinoma developed a pruritic papular eruption after her sixth pembrolizumab infusion. Examination revealed erythematous papules on the trunk and extremities with scattered vesicles. Biopsy demonstrated suprabasilar acantholysis and dyskeratosis, consistent with an ICI-induced Grover-like eruption. She was managed with systemic corticosteroids, topical steroids, antipruritic agents and gabapentin. The eruption partially improved but recurred, requiring ongoing topical therapy.
Methods
We performed a PubMed search using the terms “immune checkpoint inhibitor AND grover,” “immune checkpoint inhibitor AND transient acantholytic dermatosis,” and “immunotherapy AND transient acantholytic dermatosis.” Eleven articles met inclusion criteria, reporting histologically confirmed TAD associated with ICIs. Clinical characteristics, tumor type, ICI regimen, time to onset, treatment and outcomes were extracted.
Results
Including our case, 16 patients with ICI-induced TAD were identified. Patients were predominantly male (75%) with a mean age of 68.3 years. Melanoma was the most common malignancy (56%). Half developed eruptions on PD-1 monotherapy, with mean onset at 3.3 cycles. Topical corticosteroids were used in 93.8% and systemic corticosteroids in 56.3%. Nearly half required interruption or discontinuation of immunotherapy.
Conclusion
ICI-induced TAD is rare but often symptomatic, with management complicated by potential impact on oncologic outcomes. Early dermatology involvement and consideration of steroid-sparing agents may optimize care.
Zitieren
APA
Ghalambor, T., & Abbott, J. (2026). Pembrolizumab Induced Grover-like Eruption in a Colorectal Liver Metastasis Patient: A Case and Review. Journal of Dermatology Research, 7(2), 1-7. https://doi.org/10.46889/jdr.2026.7205
Vancouver
Ghalambor T, Abbott J. Pembrolizumab Induced Grover-like Eruption in a Colorectal Liver Metastasis Patient: A Case and Review. Journal of Dermatology Research. 2026;7(2):1-7. doi:10.46889/jdr.2026.7205
BibTeX
@article{Ghalambor2026,
author = {Ghalambor, Tara and Abbott, Jordan},
title = {Pembrolizumab Induced Grover-like Eruption in a Colorectal Liver Metastasis Patient: A Case and Review},
journal = {Journal of Dermatology Research},
year = {2026},
volume = {7},
number = {2},
pages = {1--7},
doi = {10.46889/jdr.2026.7205}
}
EUVIMED